A Monoclonal Antibody for Malaria Prevention.
Martin R GaudinskiNina M BerkowitzAzza H IdrisEmily E CoatesLaSonji A HolmanFloreliz MendozaIngelise J GordonSarah H PlummerOlga TrofymenkoZonghui HuAndrezza Campos ChagasSarah O'ConnellManjula BasappaNaomi DouekSandeep R NarpalaChristopher R BarryAlicia T WidgeRenunda HicksSeemal F AwanRichard L WuSomia HickmanDiane WycuffJudy A SteinChristopher CaseBrian P EvansKevin CarltonJason G GallSandra VazquezBritta FlachGrace L ChenJoseph R FrancicaBarbara J FlynnNeville K KisaluEdmund V CapparelliAdrian McDermottJohn R MascolaJulie E LedgerwoodRobert A Sedernull nullPublished in: The New England journal of medicine (2021)
Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 612 ClinicalTrials.gov number, NCT04206332.).